Difference between revisions of "Journal:Cannabis sativa research trends, challenges, and new-age perspectives"
Shawndouglas (talk | contribs) (Created stub; saving and adding more.) |
Shawndouglas (talk | contribs) (Saving and adding more.) |
||
| Line 8: | Line 8: | ||
|journal = ''iScience'' | |journal = ''iScience'' | ||
|authors = Hussain, Tajammul; Jeena, Ganga; Pitakbut, Thanet; Vasilev, Nikolay; Kayser, Oliver | |authors = Hussain, Tajammul; Jeena, Ganga; Pitakbut, Thanet; Vasilev, Nikolay; Kayser, Oliver | ||
|affiliations = TU Dortmund University | |affiliations = TU Dortmund University | ||
|contact = Email: Tajammul dot hussain at tu-dortmund dot de | |contact = Email: Tajammul dot hussain at tu-dortmund dot de | ||
|editors = | |editors = | ||
| Line 39: | Line 39: | ||
==Introduction== | ==Introduction== | ||
[[Cannabis sativa|''Cannabis sativa'' L.]] is one of the earliest known cultivated plants since agricultural farming started around 10,000 years ago. (Schultes et al., 1974) It is a multi-purpose crop plant with diverse agricultural and industrial applications, ranging from the production of paper, wood, and fiber, to its actual and potential use in the medicinal and pharmaceutical industries. The first-ever report to reveal the prospects of ''C. sativa'' L. as a medicinal plant was published in 1843 and described the use of plant extracts to treat patients suffering from tetanus, hydrophobia, and cholera. (O'Shaughnessy, 1843) However, the first chemical constituent identified was oxy-cannabis, in 1869 (Bolas and Francis, 1869). [[Cannabinoid]]s were being isolated as early as 1896, followed by a variety of full identifications like: | |||
* [[cannabidiol]] (CBD) in 1940 (Jacob and Todd, 1940), | |||
* [[tetrahydrocannabinol]] (THC) in 1964 (Gaoni and Mechoulam, 1964; Santavý, 1964), | |||
* [[cannabigerol]] (CBG) in 1964 (Gaoni and Mechoulam, 1966), and | |||
* [[cannabichromene]] (CBC) in 1966. (Gaoni and Mechoulam, 1966) | |||
Identification of THC later led to an understanding of the endocannabinoid system, followed by the discovery of the first cannabinoid receptor (CB1) in 1988. (Devane et al., 1988; Russo, 2016). The CB1 receptor acts as a homeostatic regulator of neurotransmitters for pain relief mechanisms, but the same mode of action was responsible for the intoxicating effects from excessive cannabinoids use. This greater understanding of the mode of action of the CB1 receptor raised concerns about the adverse effects of cannabis use. Consequently, the plant was removed from the "medicinal" category and re-categorized exclusively to the category of "[[Cannabis (drug)|illicit drug]]." | |||
[[Cannabis cultivation|Cultivation]] and use of the ''Cannabis'' plant for recreational, medical, and industrial use were strictly banned, which severely limited the scientific research in the field. Owing to strict legal regulations, the plant remained unexplored for its incredible potential in drug discovery for an extended period until it was legalized for medical use first in California and later in many countries around the globe. Extensive research followed legalization in order to explore the chemodiversity of cannabinoids for potential clinical value. In total, more than one thousand compounds have been identified, including 278 cannabinoids, 174 [[terpene]]s, 221 [[terpenoid]]s, 19 [[flavonoid]]s, 63 flavonoid glycosides, 46 polyphenols, and 92 steroids—have been identified. (ElSohly and Slade, 2005; Gould, 2015; Radwan et al., 2017) Nearly 278 of these compounds are cannabinoids and classified as phytocannabinoids (plant-based) to distinguish them from endocannabinoids (non-plant). Cannabimimetic drugs binding to CB1 receptors in the endocannabinoid system can also be found in algae, bryophytes, and monilophytes. (Carvalho, 2017; Kumar et al., 2019) The major cannabinoids in cannabis include THC, CBD, and CBC, as well as their precursors CBG and [[cannabinol]] (CBN). (Flores-Sanchez and Verpoorte, 2008) To date, 10 CBN-type, 17 CBG-type, 8 CBD-type, and 18 THC-type cannabinoids have been isolated. (Gaoni and Mechoulam, 1964) [[Cannabigerolic acid]] (CBGA), a CBG-type cannabinoid, is the central precursor for the biosynthesis of psychoactive THC, non-psychoactive CBD, and CBC. (ElSohly and Slade, 2005; Gould, 2015; Radwan et al., 2017) | |||
Cannabinoid [[biosynthesis]] in plants occurs in specialized biosynthetic organs called glandular [[trichome]]s (Happyana et al., 2013) on female [[Inflorescence|flowers]] and leaves. Several studies use metabolic profiling of trichomes to demonstrate variation in trichome size, density, and relative concentration of cannabinoids. (Happyana et al., 2013; Small and Naraine, 2016) However, the [[Genetics|genetic]] mechanisms underlying the developmental changes in trichomes and consecutive cannabinoid content are still unknown. Apart from natural and chemical biosynthesis methods (Bovens et al., 2009), heterologous biosynthesis of cannabinoids has also been reported. (Luo et al., 2019) However, the considerable amount of side products is still one of the major bottlenecks in cannabinoid production. (Luo et al., 2019; Thomas et al., 2020) | |||
This review highlights the latest research developments and challenges in ''Cannabis'' plant sciences, as well as the role of trichomes as biosynthetic sites, with a special focus on plant biology. Additionally, we discuss the existing legal practices with patent information for ''C. sativa'' L. We also discuss the new potential use of cannabinoids for [[limswiki:COVID-19|COVID-19]] treatment. Finally, we address the available genomic and transcriptomic resources and discuss their potential toward the genetic improvement of cannabis. Overall, we provide the first in-depth review of diverse aspects of ''C. sativa'' L. from traditional medicinal use to genomics insights and research perspective to broad industrial applications. | |||
Revision as of 21:54, 1 April 2022
| Full article title | Cannabis sativa research trends, challenges, and new-age perspectives |
|---|---|
| Journal | iScience |
| Author(s) | Hussain, Tajammul; Jeena, Ganga; Pitakbut, Thanet; Vasilev, Nikolay; Kayser, Oliver |
| Author affiliation(s) | TU Dortmund University |
| Primary contact | Email: Tajammul dot hussain at tu-dortmund dot de |
| Year published | 2021 |
| Volume and issue | 24(12) |
| Article # | 103391 |
| DOI | 10.1016/j.isci.2021.103391 |
| ISSN | 2589-0042 |
| Distribution license | Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International |
| Website | https://www.sciencedirect.com/science/article/pii/S2589004221013626 |
| Download | https://www.sciencedirect.com/science/article/pii/S2589004221013626/pdfft (PDF) |
 |
This article should be considered a work in progress and incomplete. Consider this article incomplete until this notice is removed. |
Abstract
Background: Cannabis sativa L. is one of the oldest known medicinal plants, cultivated for at least 10,000 years for several agricultural and industrial applications. However, the plant became controversial owing to some psychoactive components that have adverse effects on human health.
Methods: In this review, we analyze the trends in cannabis research for the past two centuries. We discuss the historical transitions of cannabis from the category of "herbal medicine" to an illicit drug and back to a medicinal product post-legalization. In addition, we address the new-age application of immuno-suppressive and anti-inflammatory cannabis extracts for the treatment of COVID-19 inflammation. We further address the influence of the legal aspects of cannabis cultivation for medicinal, pharmaceutical, and biotechnological research. Finally, we review the up-to-date cannabis-related genomic resources and advanced technologies for their potential application in genomic-based cannabis improvement.
Results: Overall, this review discusses the diverse aspects of cannabis research developments, ranging from traditional use as herbal medicine to the latest potential in COVID-19, legal practices with updated patent status, and current state of the art genetic and genomic tools reshaping cannabis biotechnology in the modern agriculture and pharmaceutical industries.
Conclusions: Remarkable growth in genomic data, combined with fast-paced development of artificial intelligence (AI)-based data analysis tools have made it possible to explore the Cannabis plant at the genetic and molecular levels. In the future, the combination of these genetic technologies will make it possible to obtain enhanced expression rates, which will lead to enhanced cannabinoid yields in an economically feasible manner. Pharmacological research, coupled with rapidly evolving genome-based biotechnology, will further facilitate exploring the Cannabis plant for its tremendous potential in drug discovery.
Keywords: cannabis, cannabis research, plant biology, plant genetics, genomics
Introduction
Cannabis sativa L. is one of the earliest known cultivated plants since agricultural farming started around 10,000 years ago. (Schultes et al., 1974) It is a multi-purpose crop plant with diverse agricultural and industrial applications, ranging from the production of paper, wood, and fiber, to its actual and potential use in the medicinal and pharmaceutical industries. The first-ever report to reveal the prospects of C. sativa L. as a medicinal plant was published in 1843 and described the use of plant extracts to treat patients suffering from tetanus, hydrophobia, and cholera. (O'Shaughnessy, 1843) However, the first chemical constituent identified was oxy-cannabis, in 1869 (Bolas and Francis, 1869). Cannabinoids were being isolated as early as 1896, followed by a variety of full identifications like:
- cannabidiol (CBD) in 1940 (Jacob and Todd, 1940),
- tetrahydrocannabinol (THC) in 1964 (Gaoni and Mechoulam, 1964; Santavý, 1964),
- cannabigerol (CBG) in 1964 (Gaoni and Mechoulam, 1966), and
- cannabichromene (CBC) in 1966. (Gaoni and Mechoulam, 1966)
Identification of THC later led to an understanding of the endocannabinoid system, followed by the discovery of the first cannabinoid receptor (CB1) in 1988. (Devane et al., 1988; Russo, 2016). The CB1 receptor acts as a homeostatic regulator of neurotransmitters for pain relief mechanisms, but the same mode of action was responsible for the intoxicating effects from excessive cannabinoids use. This greater understanding of the mode of action of the CB1 receptor raised concerns about the adverse effects of cannabis use. Consequently, the plant was removed from the "medicinal" category and re-categorized exclusively to the category of "illicit drug."
Cultivation and use of the Cannabis plant for recreational, medical, and industrial use were strictly banned, which severely limited the scientific research in the field. Owing to strict legal regulations, the plant remained unexplored for its incredible potential in drug discovery for an extended period until it was legalized for medical use first in California and later in many countries around the globe. Extensive research followed legalization in order to explore the chemodiversity of cannabinoids for potential clinical value. In total, more than one thousand compounds have been identified, including 278 cannabinoids, 174 terpenes, 221 terpenoids, 19 flavonoids, 63 flavonoid glycosides, 46 polyphenols, and 92 steroids—have been identified. (ElSohly and Slade, 2005; Gould, 2015; Radwan et al., 2017) Nearly 278 of these compounds are cannabinoids and classified as phytocannabinoids (plant-based) to distinguish them from endocannabinoids (non-plant). Cannabimimetic drugs binding to CB1 receptors in the endocannabinoid system can also be found in algae, bryophytes, and monilophytes. (Carvalho, 2017; Kumar et al., 2019) The major cannabinoids in cannabis include THC, CBD, and CBC, as well as their precursors CBG and cannabinol (CBN). (Flores-Sanchez and Verpoorte, 2008) To date, 10 CBN-type, 17 CBG-type, 8 CBD-type, and 18 THC-type cannabinoids have been isolated. (Gaoni and Mechoulam, 1964) Cannabigerolic acid (CBGA), a CBG-type cannabinoid, is the central precursor for the biosynthesis of psychoactive THC, non-psychoactive CBD, and CBC. (ElSohly and Slade, 2005; Gould, 2015; Radwan et al., 2017)
Cannabinoid biosynthesis in plants occurs in specialized biosynthetic organs called glandular trichomes (Happyana et al., 2013) on female flowers and leaves. Several studies use metabolic profiling of trichomes to demonstrate variation in trichome size, density, and relative concentration of cannabinoids. (Happyana et al., 2013; Small and Naraine, 2016) However, the genetic mechanisms underlying the developmental changes in trichomes and consecutive cannabinoid content are still unknown. Apart from natural and chemical biosynthesis methods (Bovens et al., 2009), heterologous biosynthesis of cannabinoids has also been reported. (Luo et al., 2019) However, the considerable amount of side products is still one of the major bottlenecks in cannabinoid production. (Luo et al., 2019; Thomas et al., 2020)
This review highlights the latest research developments and challenges in Cannabis plant sciences, as well as the role of trichomes as biosynthetic sites, with a special focus on plant biology. Additionally, we discuss the existing legal practices with patent information for C. sativa L. We also discuss the new potential use of cannabinoids for COVID-19 treatment. Finally, we address the available genomic and transcriptomic resources and discuss their potential toward the genetic improvement of cannabis. Overall, we provide the first in-depth review of diverse aspects of C. sativa L. from traditional medicinal use to genomics insights and research perspective to broad industrial applications.
References
Notes
This presentation is faithful to the original, with only a few minor changes to presentation. References aren't listed in the order they appear in the original, but they do for this version, by design. In some cases important information was missing from the references, and that information was added. A few words were added, updated, or shifted for improved grammar and readability, but this version is otherwise unchanged in compliance with the "NoDerivatives" portion of the original's license.
